Sage Journals: Discover world-class research

Open access

Research article

First published 2020-7

Anti-JCV antibody index does not change during ocrelizumab-treatment

Torge Rempe, Aaron Carlson, Augusto Miravalle [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2016-7

PML risk stratification using anti-JCV antibody index and L-selectin

Nicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2016-12

Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy

A. Salmen, N. von Ahsen, A.K. Trampe [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2025

Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV antibody detection in natalizumab-treated RRMS patients

Clara Grazia Chisari, Giulio Spampinato, Pina Crimì [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Research article

First published 2015-10

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

Anke Vennegoor, Johannis A van Rossum, Chris H Polman [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2004-9

Quantitative Representation of Alternative Movement Techniques and Motion Variability

Woojin Park, Don B. Chaffin, Bernard J. Martin [...]

Proceedings of the Human Factors and Ergonomics Society Annual Meeting

Retricted access

Research article

First published 2024-10

Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres

Gloria Dalla Costa, Letizia Leocani, Marco Pisa [...]

Multiple Sclerosis Journal

Retricted access

Review article

First published 2018-4

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters

Nicholas Schwab, Tilman Schneider-Hohendorf, Tammy Hoyt [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2014-6

JC-virus seroconversion in multiple sclerosis patients receiving natalizumab

Olivier Outteryck, Hélène Zéphir, Julia Salleron [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2015-12

Anti-JC virus antibody titres increase over time with natalizumab treatment

J Raffel, AR Gafson, O Malik [...]

Multiple Sclerosis Journal

Search results